{
  "id": "63f741a633942b094c000009",
  "type": "list",
  "question": "What are the active components of Opdualag?",
  "ideal_answer": "Opdualag is a new dual anti-PD-1 (Nivolumab) and anti-LAG-3 (Relatimab) treatment approved as the first LAG-3 blocking antibody combination for unresectable or metastatic melanoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/36268952",
    "http://www.ncbi.nlm.nih.gov/pubmed/35543970",
    "http://www.ncbi.nlm.nih.gov/pubmed/35954196"
  ],
  "snippets": [
    {
      "text": "Recently, a new dual anti-PD-1 (Nivolumab) and anti-LAG-3 (Relatimab) treatment developed by Bristol Myers Squibb (Opdualag), was approved by the Food and Drug Administration (FDA) as the first LAG-3 blocking antibody combination for unresectable or metastatic melanoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35954196",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nivolumab plus relatlimab (nivolumab and relatlimab-rmbw; Opdualag\u2122) is a fixed-dose, combination immunotherapy treatment being developed by Bristol Myers Squibb for the treatment of multiple types of advanced cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35543970",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "DATA SOURCES: A search of PubMed conducted from August 2019 to August 2022 with the search terms Opdualag, nivolumab AND relatlimab, and BMS-986016 resulted in 14 publications.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36268952",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Nivolumab, Relatimab"
}